×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 8, Track C: Vanessa's Law: Impact and Challenges of Mandatory Adverse Reaction Reporting
Session Chair(s)
Marcia Bailey, BSN, MHS, RN
Safety Evaluation and Risk Management Scientific Director
GSK, Canada
Vanessa Zapata
Associate Director, Regional Pharmacovigilance Officer
Merck Canada Inc., Canada
Vanessa’s Law (Bill C-17) became effective in 2014. This session provides an overview of Health Canada’s perspective and expectations regarding implementation of the law and its impact on health care facilities. This session will also include challenges that the pharmaceutical industry is currently facing.
Learning Objective : At the conclusion of this session, participants should be able to:- Explain Health Canada’s expectation regarding the implementation of Vanessa’s Law
- Identify the actions required by health care facilities to be compliant with Vanessa’s Law
- Describe challenges faced by the Industry following the implementation of Vanessa’s Law
Speaker(s)
Vanessa's Law: Impact and Challenges of Mandatory Adverse Reaction Reporting, from an Industry Perspective
Aurela Balla, DrMed
Merck Canada Inc., Canada
Senior Director, Pharmacovigilance
Health Canada Refresher: Mandatory Reporting of Medical Device Incidents (MDIs) and Serious Adverse Drug Reactions (ADRs) by Hospitals
Marie-Claude Brutus Lopez, RPh
Health Canada, Canada
Coordinator, Canada Vigilance Program, Marketed Health Products Directorate
Have an account?